Abstract
Targeted antigen delivery to immune cells, particularly dendritic cells, has emerged as a promising strategy to enhance therapeutic efficacy of vaccines, while minimizing adverse effects associated with conventional immunization. In this study, we use our previously described small glycomimetic molecule that is selectively recognized by the Langerhans cell (LC)-specific surface receptor Langerin and demonstrate specific delivery of protein antigens to these specialized dendritic cells. Our results show that Langerin-mediated antigen delivery significantly enhances the immune response in vivo, resulting in increased expansion and activation of antigen-specific T cells, compared to immunization with unmodified antigen. We demonstrate the feasibility of our LC-targeted platform for immune cell-specific immunization with protein antigen and underscore the potential of LCs as an access point for next-generation vaccines and immunotherapies.
| Original language | English |
|---|---|
| Pages (from-to) | 397-406 |
| Number of pages | 10 |
| Journal | Molecular therapy : the journal of the American Society of Gene Therapy |
| Volume | 34 |
| Issue number | 1 |
| Early online date | 4 Oct 2025 |
| DOIs | |
| Publication status | Published - 7 Jan 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Austrian Fields of Science 2012
- 301902 Immunology
- 301903 Vaccine development
Keywords
- intradermal vaccination
- Langerhans cells
- skin dendritic cells
- targeted antigen delivery
Fingerprint
Dive into the research topics of 'Langerhans cell-targeted protein delivery enhances antigen-specific cellular immune response'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver